Drug intelligence / Profile preview

HH-001

Development stage: Preclinical
Lead developer: QingHe Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

HH-001 is a humanized monoclonal antibody targeting Ubiquitin Specific Peptidase 22 (USP22), currently in preclinical development by QingHe Biotech for the treatment of androgenetic alopecia and alopecia areata. USP22 is a deubiquitinating enzyme that plays a critical role in protein stability and cell signaling pathways. HH-001 is designed to promote hair growth and follicle regeneration by modulating USP22 activity, which is thought to influence the hair follicle cycle. The drug is intended for subcutaneous administration.

Targets

USP22 (Ubiquitin-specific peptidase 22)

Beyond the preview

Go deeper on HH-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HH-001.

Explore the full profile